Chemistry Nobel Honors AlphaFold and Protein Design

The 2024 Nobel Prize in Chemistry recognizes a transformation that had been taking shape in laboratories for decades: using computers and artificial intelligence to understand and create proteins. Half of the award goes to David Baker of the University of Washington, while the other half is shared by Demis Hassabis and John Jumper of Google DeepMind, the creators of AlphaFold.

The Royal Swedish Academy of Sciences has recognized Baker for computational protein design and Hassabis and Jumper for protein structure prediction. The award places AI at the center of a field where knowing the shape of a molecule can be just as important as knowing its composition.

The shape that determines function

Proteins are long chains of amino acids. Once produced by cells, those chains fold into three-dimensional structures. That geometry determines, for example, whether a protein transports oxygen, speeds up a chemical reaction or binds to a virus.

The problem is that predicting this shape from an amino acid sequence has been one of biology’s great challenges. For decades, determining a protein’s structure required complex and expensive experiments, such as X-ray crystallography, nuclear magnetic resonance or cryo-electron microscopy. These techniques remain fundamental, but they cannot keep pace with the rate at which genetic sequences are being discovered.

AlphaFold changed the relationship between biological data and structure. DeepMind’s first version made headlines at CASP in 2018, an international assessment that compares prediction methods. AlphaFold2, introduced in 2020, marked the decisive leap: for many proteins, it achieved accuracy close to that of experimental methods.

The system analyzes a protein’s sequence and large databases of evolutionarily related proteins. Using that information, it estimates which parts of the chain will be close to one another and builds a prediction of its structure. It does not physically observe the molecule; it infers its shape from patterns learned from biological data.

From a demonstration to scientific infrastructure

The recognition is not just for a competition result. DeepMind and the European Molecular Biology Laboratory, through its European Bioinformatics Institute, launched the AlphaFold Protein Structure Database. The platform provides predictions for more than 200 million proteins, freely accessible to researchers around the world.

That does not make every prediction a definitive structure. AlphaFold accompanies its results with confidence scores and performs less well in some flexible regions of proteins or in systems where interactions between multiple molecules are especially important. Experiments are still needed to verify results, study specific mechanisms and develop medicines.

But the practical difference is enormous. A team can now consult a structural hypothesis within minutes before deciding which experiments are worth carrying out. In basic research, this can help assign functions to poorly studied proteins. In medicine, it facilitates the analysis of disease-linked mutations and the study of drug targets. In biotechnology, it speeds the search for enzymes capable of carrying out industrial reactions or breaking down pollutants.

David Baker and the proteins that never existed

The other half of the Nobel recognizes a different but complementary step: not limiting research to deciphering natural proteins, but designing new ones with a specific function.

David Baker has spent decades developing Rosetta, a suite of computational methods for modeling and designing proteins. In 2003, his group presented Top7, a computer-designed protein whose structure did not resemble any known in nature. It showed that the physical and chemical rules governing folding could be used in reverse: starting with a desired function or shape and searching for a sequence capable of producing it.

This capability opens the door to proteins designed for specific tasks: more efficient catalysts, materials with novel properties, sensors or therapeutic molecules. Baker’s research has also helped fuel current tools that combine machine-learning models with physics-based simulations to propose thousands of candidates and select which ones to make and test in the laboratory.

A Nobel for a hybrid science

The prize awards 11 million Swedish kronor among the three researchers and sends a clear signal: AI is no longer just a tool for classifying images, writing text or recommending content. It has also become an instrument for formulating hypotheses in the natural sciences.

That advance should not be mistaken for a replacement for experimental research. AlphaFold and protein-design systems depend on data accumulated by biologists, chemists and structural biologists over decades. Their greatest value lies in making that work more productive: narrowing the space of possibilities, suggesting explanations and guiding experiments.

For Google DeepMind, the Nobel also reinforces a direction that departs from the usual competition over conversational assistants. The company introduced AlphaFold3 last May, a new generation designed to model interactions between proteins, DNA, RNA and small molecules. The challenge now will be to translate that predictive capability into verifiable results in laboratories, treatments and industrial processes.